Gastroretentive Drug Delivery Systems Outsourcing Market Report 2026

Gastroretentive Drug Delivery Systems Outsourcing Market Overview

• Gastroretentive Drug Delivery Systems Outsourcing market size has reached to $1.49 billion in 2025 • Expected to grow to $2.1 billion in 2030 at a compound annual growth rate (CAGR) of 6.9% • Growth Driver: Rising Prevalence Of Gastrointestinal Disorders Drives Growth In Gastroretentive Drug Delivery Systems Outsourcing Market • Market Trend: Innovative Products Driving Growth In Gastroretentive Drug Delivery Systems Outsourcing Market • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Gastroretentive Drug Delivery Systems Outsourcing Market?

Gastroretentive drug delivery systems outsourcing refers to the practice of pharmaceutical companies contracting with external service providers or contract research organizations (CROs) to develop and manufacture drug delivery systems designed to prolong the residence time of medications within the gastrointestinal (GI) tract. These systems are engineered to enhance drug absorption, improve therapeutic efficacy, and optimize patient outcomes. The main types of gastroretentive drug delivery systems outsourcing market are floating systems, bioadhesive systems, and other types. A floating drug delivery system (FDDS) is a type of drug delivery system designed to prolong the residence time of drugs in the stomach and upper gastrointestinal tract. The various dosage forms are tablets, liquid, microspheres, capsules, and other dosage forms used for various applications such as gastroesophageal reflux disease (GERD), neurological disorders, and other applications and used by various end users including pharmaceutical companies, contract research organizations (CROS), and other end users.

What Is The Gastroretentive Drug Delivery Systems Outsourcing Market Growth Forecast?

The gastroretentive drug delivery systems outsourcing market size is expected to see strong growth in the next few years. It will grow to $2.1 billion in 2030 at a compound annual growth rate (CAGR) of 6.9%. The growth in the forecast period can be attributed to increasing complex drug molecules, demand for patient-centric delivery systems, expansion of outsourcing strategies, innovation in gastroretentive technologies, cost optimization by pharma companies. Major trends in the forecast period include growing outsourcing of advanced drug delivery development, increased demand for prolonged gi retention formulations, rising adoption of floating drug delivery systems, expansion of cro partnerships in formulation development, focus on enhanced drug bioavailability.

Global Gastroretentive Drug Delivery Systems Outsourcing Market Segmentation

1) By Type: Floating Systems, Bioadhesive Systems, Other Types 2) By Dosage Form: Tablets, Liquid, Microspheres, Capsule, Other Dosage Forms 3) By Application: Gastroesophageal Reflux Disease (GERD), Neurological Disorders, Other Applications 4) By End User: Pharmaceutical Companies, Contract Research Organizations (CROs), Other End Users Subsegments: 1) By Floating Systems: Single Unit Systems, Multiple Unit Systems 2) By Bioadhesive Systems: Hydrogels, Mucoadhesive Polymers 3) By Other Types: Magnetically Assisted Systems, High-Density Systems, Osmotic Systems

What Are The Drivers Of The Gastroretentive Drug Delivery Systems Outsourcing Market?

The rising prevalence of gastrointestinal disorders is expected to propel the growth of the gastroretentive drug delivery systems outsourcing market going forward. Gastrointestinal disorders refer to a wide range of diseases affecting the digestive tract, which includes the stomach, liver, gallbladder, intestines, and pancreas. Gastrointestinal disorders are rising due to aging populations, antibiotic use, infectious agents, dietary changes, stress and lifestyle factors, and obesity. Outsourcing gastroretentive drug delivery systems provides pharmaceutical companies with the resources and expertise needed to address the growing burden of gastrointestinal disorders, ultimately improving patient outcomes and quality of life. For instance, in August 2023, according to the National Institute of Diabetes and Digestive and Kidney Diseases, a US-based government‑funded research institute and public health agency, reported that 60 to 70 million people affected by all digestive diseases. Therefore, the rising prevalence of gastrointestinal disorders is driving the gastroretentive drug delivery systems outsourcing industry. The increasing prevalence of age related disorders is expected to drive the growth of the gastroretentive drug delivery systems going forward. Age related disorders refer to a broad spectrum of medical conditions and functional impairments that predominantly affect older adults, including cardiovascular diseases, neurodegenerative disorders, musculoskeletal conditions, and sensory impairments. The incidence of these disorders is rising due to aging populations, longer life expectancy, lifestyle factors, and chronic disease accumulation. For instance, in April 2025, according to the Centers for Disease Control and Prevention, a US-based government public health agency, reported that in 2023, approximately 194 million American adults, including 6 in 10 young adults, 8 in 10 midlife adults, and 9 in 10 older adults, reported 1 or more conditions. Prevalence of chronic conditions increased by 7.0 percentage points among young adults. Therefore, increasing prevalence of age related disorders is driving the gastroretentive drug delivery systems outsourcing industry.

Key Players In The Global Gastroretentive Drug Delivery Systems Outsourcing Market

Major companies operating in the gastroretentive drug delivery systems outsourcing market are Pfizer Inc., Merck & Co. Inc., Sanofi S.A., AstraZeneca plc, Novartis AG, Evonik Industries AG, SGS SA, Lonza Group AG, Sun Pharmaceutical Industries Ltd., Catalent Inc., AptarGroup Inc., Cadila Pharmaceuticals, Ashland Global Holdings Inc, Lupin Limited, Torrent Pharmaceuticals Ltd., Evotec SE, Colorcon Inc., Quotient Sciences Limited, Aenova Group, Vectura Group Ltd., Coating Place Inc., Xiromed LLC, SPI Pharma Inc.

Global Gastroretentive Drug Delivery Systems Outsourcing Market Trends and Insights

Major companies operating in the gastroretentive drug delivery systems outsourcing market are focused on developing innovative products, such as ready-to-fill (RTF) colon functional capsules to enhance drug delivery efficiency and patient convenience. The ready-to-fill (RTF) colon functional capsules refers to pre-manufactured, empty capsules that are designed to be filled with specific formulations or active ingredients tailored for the colon. For instance, in September 2024, Evonik, a Germany-based advanced drug delivery provider, launched EUDRACAP colon functional capsules, designed for the targeted delivery of oral drugs to the ileo-colonic region. These innovative capsules are the first ready-to-fill option available in the market, aimed at delivering sensitive active ingredients such as live biotherapeutic products (LBPs). Currently offered in technical grade, a GMP-grade product is also in development. EUDRACAP colon enhances the oral drug development process by simplifying formulation and accelerating time to market, making it a significant advancement in gastroretentive drug delivery systems.

Regional Outlook

North America was the largest region in the gastroretentive drug delivery systems outsourcing market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Gastroretentive Drug Delivery Systems Outsourcing Market?

The gastroretentive drug delivery systems outsourcing market consists of revenues earned by entities by providing services such as formulation development, analytical and testing services, quality assurance and control, and clinical trial services. The market value includes the value of related goods sold by the service provider or included within the service offering. The gastroretentive drug delivery systems outsourcing market also includes sales of bioadhesive systems, swelling systems, and high-density systems, and floating systems. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Gastroretentive Drug Delivery Systems Outsourcing Market Report 2026?

The gastroretentive drug delivery systems outsourcing market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the gastroretentive drug delivery systems outsourcing industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.